Drug Enforcement Administration
Audit of the Department of Justice Policy on Body Worn Cameras
The Office of the Inspector General is initiating an audit of the Department of Justice (Department) Policy on Body Worn Cameras. Our preliminary objectives are to: (1) review and assess the Department’s current body worn camera policy for federal law enforcement officers, (2) evaluate the extent to which body worn cameras were utilized during the Department’s task force pilot program, and (3) assess any plans to expand the use of body worn cameras among federal law enforcement officers and federally deputized task force participants.
Audit of the Drug Enforcement Administration's Community-Based Efforts to Combat the Opioid Crisis
The OIG is conducting an audit of the DEA's community-based efforts to combat the opioid crisis. The preliminary objectives are to: (1) examine the DEA’s pilot city-selection methodology, (2) assess the DEA’s integration of a performance measurement strategy to enhance its community-based efforts, (3) evaluate the DEA’s collaboration with other agencies in combatting the opioid crisis, and (4) assess the DEA’s efforts to sustain progress in the communities it assists.
Audit of the Drug Enforcement Administration's Establishment and Oversight of DEA-Supported Foreign Law Enforcement Units
The OIG is conducting an audit of the Drug Enforcement Administration’s (DEA) establishment and oversight of DEA-supported foreign law enforcement units. The preliminary objectives are to: (1) evaluate the DEA’s process for establishing supported law enforcement units abroad, such as Sensitive Investigative Units, Vetted Units, and Protected Police Units; (2) determine if the DEA is effectively overseeing these units and safeguarding funds used to sustain these formal relationships; and (3) assess the DEA’s process for addressing allegations and specific instances of mismanagement, malfeasance, and waste associated with these units.
Audit of the Drug Enforcement Administration's Support Contracts for its Laboratory Information Management System
The OIG is auditing the Drug Enforcement Administration’s (DEA) support contracts for its Laboratory Information Management System (LIMS). The preliminary audit objective is to assess DEA’s administration of a bridge contract awarded to Abbott Informatics Corporation (Abbott) in March 2019, and relevant acquisition planning activities associated with a solicitation issued in November 2019. To accomplish this objective, we anticipate reviewing DEA’s plans for and oversight of LIMS support contracts, Abbott’s performance on the bridge contract, and pertinent performance and financial reporting requirements.
DEA's Prescription Drug Take Back Activities
The OIG is auditing DEA’s prescription drug take back activities. The preliminary objective is to evaluate the DEA’s policies, procedures, and practices for the collection, custody, and disposal of prescription drugs.
Survey on the Effects of COVID-19 on ATF, DEA, FBI, USAO, and USMS Investigative Operations
The Office of the Inspector General is initiating a survey to the ATF, DEA, FBI, USAOs, and USMS to better understand the effects of COVID-19 on investigative operations.
To detect and deter waste, fraud, abuse, and misconduct in DOJ programs and personnel, and to promote economy and efficiency in those programs.